Revolution Medicines (42Z) Stock Forecast & Price Target

Compare

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

42Z Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Revolution

Medicines

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

42Z Stock 12 Month Forecast

Average Price Target

€60.75

▲(68.76% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is €60.75 with a high forecast of €68.24 and a low forecast of €32.34. The average price target represents a 68.76% change from the last price of €36.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"30":"€30","69":"€69","39.75":"€39.8","49.5":"€49.5","59.25":"€59.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":68.2416264,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€68.24</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":60.7521079026,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€60.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.3380007103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€32.34</span>\n  </div></div>","useHTML":true}}],"tickPositions":[30,39.75,49.5,59.25,69],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,34.787817415384616,37.57563483076923,40.36345224615385,43.151269661538464,45.93908707692308,48.726904492307696,51.514721907692305,54.30253932307693,57.09035673846154,59.87817415384616,62.66599156923077,65.45380898461539,{"y":68.2416264,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,34.21170060789231,36.423401215784615,38.635101823676926,40.84680243156923,43.05850303946154,45.27020364735385,47.48190425524616,49.69360486313846,51.90530547103077,54.11700607892308,56.32870668681539,58.5404072947077,{"y":60.7521079026,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,32,32.02600005463846,32.052000109276925,32.078000163915384,32.10400021855385,32.13000027319231,32.15600032783077,32.182000382469234,32.20800043710769,32.23400049174615,32.26000054638462,32.286000601023076,32.31200065566154,{"y":32.3380007103,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.2,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.8,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.2,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":35.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.2,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.2,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€68.24

Average Price Target€60.75

Lowest Price Target€32.34

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Peter Lawson

Barclays

€61.71

Buy

71.41%

Upside

Reiterated

09/26/25

Barclays Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Brian Cheng

J.P. Morgan

€60.85

Buy

69.03%

Upside

Reiterated

09/25/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/25/25

Revolution Medicines (RVMD) Receives a Buy from Truist Financial

Sean McCutcheon

Raymond James

€61.71

Buy

71.41%

Upside

Initiated

09/12/25

Revolution Medicines resumed with a Strong Buy at Raymond JamesRevolution Medicines resumed with a Strong Buy at Raymond James

Ami Fadia

Needham

€47.99→€56.56

Buy

57.12%

Upside

Reiterated

09/11/25

Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines

Eva Fortea Verdejo

Wells Fargo

€57.42→€59.99

Buy

66.64%

Upside

Reiterated

09/11/25

Revolution Medicines price target raised to $70 from $67 at Wells FargoRevolution Medicines price target raised to $70 from $67 at Wells Fargo

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

09/11/25

TD Cowen Keeps Their Buy Rating on Revolution Medicines (RVMD)

Kelsey Goodwin

Piper Sandler

€64.28

Buy

78.55%

Upside

Reiterated

09/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)

Robert Driscoll

Wedbush

€62.56→€65.99

Buy

83.31%

Upside

Reiterated

09/11/25

Wedbush Remains a Buy on Revolution Medicines (RVMD)

Alec Stranahan

Bank of America Securities

€66.85

Buy

85.69%

Upside

Reiterated

09/11/25

Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT) and Revolution Medicines (NASDAQ: RVMD)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

09/11/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Travere Therapeutics (TVTX)

Charles Zhu

LifeSci Capital

€68.56

Buy

90.45%

Upside

Reiterated

09/10/25

Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines

Jay Olson

Oppenheimer

€64.28

Buy

78.55%

Upside

Reiterated

08/25/25

Oppenheimer Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Robert Burns

H.C. Wainwright

€61.71

Buy

71.41%

Upside

Reiterated

08/08/25

H.C. Wainwright Sticks to Its Buy Rating for Revolution Medicines (RVMD)2Q25 Financials Reported; Reiterate Buy – We reiterate our Buy rating and 12‐month price target of $72 per share.

Michael Schmidt

Guggenheim

€68.56

Buy

90.45%

Upside

Reiterated

08/07/25

Guggenheim Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Peter Lawson

Barclays

€61.71

Buy

71.41%

Upside

Reiterated

09/26/25

Barclays Sticks to Their Buy Rating for Revolution Medicines (RVMD)

Brian Cheng

J.P. Morgan

€60.85

Buy

69.03%

Upside

Reiterated

09/25/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

09/25/25

Revolution Medicines (RVMD) Receives a Buy from Truist Financial

Sean McCutcheon

Raymond James

€61.71

Buy

71.41%

Upside

Initiated

09/12/25

Revolution Medicines resumed with a Strong Buy at Raymond JamesRevolution Medicines resumed with a Strong Buy at Raymond James

Ami Fadia

Needham

€47.99→€56.56

Buy

57.12%

Upside

Reiterated

09/11/25

Promising Potential of Daraxonrasib in Pancreatic Cancer Boosts Buy Rating for Revolution Medicines

Eva Fortea Verdejo

Wells Fargo

€57.42→€59.99

Buy

66.64%

Upside

Reiterated

09/11/25

Revolution Medicines price target raised to $70 from $67 at Wells FargoRevolution Medicines price target raised to $70 from $67 at Wells Fargo

Marc Frahm

TD Cowen

―

Buy

―

Reiterated

09/11/25

TD Cowen Keeps Their Buy Rating on Revolution Medicines (RVMD)

Kelsey Goodwin

Piper Sandler

€64.28

Buy

78.55%

Upside

Reiterated

09/11/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Travere Therapeutics (NASDAQ: TVTX), Revolution Medicines (NASDAQ: RVMD) and Sarepta Therapeutics (NASDAQ: SRPT)

Robert Driscoll

Wedbush

€62.56→€65.99

Buy

83.31%

Upside

Reiterated

09/11/25

Wedbush Remains a Buy on Revolution Medicines (RVMD)

Alec Stranahan

Bank of America Securities

€66.85

Buy

85.69%

Upside

Reiterated

09/11/25

Analysts Conflicted on These Healthcare Names: Certara (NASDAQ: CERT) and Revolution Medicines (NASDAQ: RVMD)

Jonathan Chang

Leerink Partners

―

Buy

―

Reiterated

09/11/25

Analysts Are Bullish on These Healthcare Stocks: Revolution Medicines (RVMD), Travere Therapeutics (TVTX)

Charles Zhu

LifeSci Capital

€68.56

Buy

90.45%

Upside

Reiterated

09/10/25

Promising Clinical Trials and Strategic Design Drive Buy Rating for Revolution Medicines

Jay Olson

Oppenheimer

€64.28

Buy

78.55%

Upside

Reiterated

08/25/25

Oppenheimer Sticks to Its Buy Rating for Revolution Medicines (RVMD)

Robert Burns

H.C. Wainwright

€61.71

Buy

71.41%

Upside

Reiterated

08/08/25

H.C. Wainwright Sticks to Its Buy Rating for Revolution Medicines (RVMD)2Q25 Financials Reported; Reiterate Buy – We reiterate our Buy rating and 12‐month price target of $72 per share.

Michael Schmidt

Guggenheim

€68.56

Buy

90.45%

Upside

Reiterated

08/07/25

Guggenheim Reaffirms Their Buy Rating on Revolution Medicines (RVMD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+11.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +11.40% per trade.

3 Months

xxx

Success Rate

9/14 ratings generated profit

Average Return

+9.54%

reiterated a xxx

rating 19 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 64.29% of your transactions generating a profit, with an average return of +9.54% per trade.

1 Year

Michael SchmidtGuggenheim

Success Rate

7/9 ratings generated profit

Average Return

+10.49%

reiterated a buy rating 2 months ago

Copying Michael Schmidt's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +10.49% per trade.

2 Years

xxx

Success Rate

15/18 ratings generated profit

Average Return

+44.21%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 83.33% of your transactions generating a profit, with an average return of +44.21% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

42Z Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 42Z has received 35 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 42Z average Analyst price target in the past 3 months is 60.75.

Each month's total comprises the sum of three months' worth of ratings.

42Z Financial Forecast

42Z Earnings Forecast

Next quarter’s earnings estimate for 42Z is -€1.20 with a range of -€1.35 to -€0.98. The previous quarter’s EPS was -€1.12. 42Z beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 42Z has Preformed in-line its overall industry.

42Z Sales Forecast

Next quarter’s sales forecast for 42Z is €1.66M with a range of €0.00 to €17.71M. The previous quarter’s sales results were €0.00. 42Z beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 42Z has Preformed in-line its overall industry.

42Z Stock Forecast FAQ

What is DE:42Z’s average 12-month price target, according to analysts?

Based on analyst ratings, Revolution Medicines’s 12-month average price target is 60.75.

What is DE:42Z’s upside potential, based on the analysts’ average price target?

Revolution Medicines has 68.76% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Revolution Medicines a Buy, Sell or Hold?

Revolution Medicines has a consensus rating of Strong Buy, which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Revolution Medicines’s share price target?

The average share price target for Revolution Medicines is 60.75. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €68.24 ,and the lowest forecast is €32.34. The average share price target represents 68.76% Increase from the current price of €36.

What do analysts say about Revolution Medicines?

Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of Revolution Medicines?

To buy shares of DE:42Z, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Revolution Medicines (42Z) Stock Forecast & Price Target

42Z Analyst Ratings

42Z Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Revolution Medicines

42Z Analyst Recommendation Trends

42Z Financial Forecast

42Z Earnings Forecast

42Z Sales Forecast

42Z Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts